[et_pb_section fb_built=”1″ _builder_version=”4.22.1″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.22.1″ _module_preset=”default” background_color=”#F7F7F7″ global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.22.1″ _module_preset=”default” custom_margin=”||0px||false|false” global_colors_info=”{}”]
For LEARN Study-related papers and other publications, please see the LEARN Study Team lists
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ _module_preset=”21a9a69a-d9f7-4bcf-894a-e952230c23d9″ global_colors_info=”{}”]The LEARN Study[/et_pb_text][et_pb_image src=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF9mZWF0dXJlZF9pbWFnZSIsInNldHRpbmdzIjp7fX0=@” _builder_version=”4.16″ _dynamic_attributes=”src” _module_preset=”default” max_height=”200px” global_colors_info=”{}”][/et_pb_image][et_pb_text _builder_version=”4.21.0″ _module_preset=”default” global_colors_info=”{}”]
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration – the LEARN Study
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ _module_preset=”default” max_width=”900px” module_alignment=”center” global_colors_info=”{}”]
About the Learn Study
[/et_pb_text][et_pb_text _builder_version=”4.22.1″ _module_preset=”default” max_width=”900px” module_alignment=”center” global_colors_info=”{}”]
The LEARN study was a multicenter, observational study that evaluated the rate of cognitive change in 540 clinically normal older individuals who “screen-failed” for the A4 trial. Meaning they did not meet enrollment criteria based on their PET imaging because they did not show evidence of elevated amyloid accumulation (Aβ negative). LEARN participants did meet all other A4 study eligibility criteria. This study leveraged the A4 infrastructure and maximized the data acquired in screening from a large number of well-characterized older adults for the A4 trial.
The LEARN observational cohort provides a critical comparison group for the A4 placebo arm, and future trials in preclinical AD. Although accumulating longitudinal data suggest that older individuals with elevated Aβ burden are at increased risk of cognitive decline, it is important to demonstrate a differential rate of clinical decline between Aβe (“Aβ elevated”) and Aβne (“Aβ not elevated”) individuals on a standardized set of clinical outcomes. Over 15,000 well-characterized, highly motivated older volunteers “screen failed” for the A4 trial. The LEARN study followed 540 of these individuals, matched as closely as possible to the two treatment arms, in this observation cohort. The LEARN study selectively recruited from a specific range of SUVr that fall below the threshold for “elevated amyloid” in order to support analyses of the relationship of baseline SUVr to subsequent cognitive change and amyloid accumulation. The observational cohort were followed for 384 weeks with identical clinical/cognitive testing performed every 24 weeks, running parallel to the A4 treatment study and open label extension.
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row module_id=”lists” _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ _module_preset=”default” max_width=”900px” module_alignment=”center” global_colors_info=”{}”]
Study team lists
[/et_pb_text][et_pb_text _builder_version=”4.22.1″ _module_preset=”default” max_width=”900px” module_alignment=”center” locked=”off” global_colors_info=”{}”]
The A4 and LEARN Study Leadership Teams provide the list below for standardized acknowledgement of the many individuals who have contributed to the A4 and LEARN Studies (current and former). Please download the lists of the study teams below:
Longitudinal as of May 2023 – Journal Version
Screening as of August 2018 – Journal Version
[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.22.1″ _module_preset=”default” max_width=”900px” module_alignment=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]
Read More
Brigham & Womens Press Release- A4 Study Solanezumab Results March 2023
Eli Lilly Press Release- A4 Study Solanezumab Results March 2023
Selected Slides Study Results- A4 Study Alzheimer Association International Conference July 2023[/et_pb_text][et_pb_text _builder_version=”4.22.1″ _module_preset=”default” max_width=”900px” module_alignment=”center” global_colors_info=”{}”]
Access data from the study at a4studydata.org
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” global_module=”2826″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”/studies/” button_text=”Back to STUDIES” _builder_version=”4.19.2″ _module_preset=”d2822aae-eec8-457e-833b-5377df655e55″ global_colors_info=”{}”][/et_pb_button][/et_pb_column][/et_pb_row][/et_pb_section]